What Nonacus does

Nonacus Limited is a Birmingham, UK-based medical products manufacturer founded in 2015 that develops non-invasive NGS-based diagnostic tools for cancer. The company's core technology is Cell3 Target, a target enrichment chemistry for next-generation sequencing library preparation compatible with gDNA, cfDNA, and FFPE samples, with built-in Unique Molecular Identifiers (UMIs) that enable detection of somatic variants down to 0.1% Variant Allele Frequency from as little as 10 ng of input DNA. Building on this chemistry, Nonacus has developed the GALEAS platform, which combines targeted panels (GALEAS Bladder covering 23 genes across 96% of bladder cancers, GALEAS Tumor covering 519 genes for solid tumor profiling including HRD/TMB/MSI/CNV, and GALEAS Hereditary covering 38 genes) with cloud-based bioinformatics for end-to-end sample-to-report workflows. The GALEAS Bladder test is validated on 710+ clinical samples with >90% sensitivity across all stages and grades, is included in the European Association of Urology Guidelines, and can reportedly reduce cystoscopy procedures by ~90%, against a backdrop where flexible cystoscopy costs the NHS £88 million annually.

The company operates a dual business model: (1) a products business selling RUO NGS kits, custom panels designed via an online Panel Design Tool (1,000+ designs to date), pre-analytical cfDNA collection tubes and extraction kits, and UKCA-marked in vitro diagnostic products (GALEAS Bladder and GALEAS Tumor), distributed directly to UK NHS and private hospitals and through a 20+ country distributor network across Asia Pacific, Europe, and the Middle East; and (2) a clinical services business operated through Nonacus Clinical Services (formerly Informed Genomics, rebranded May 2025), which is UKAS-accredited to ISO 15189:2022 and delivers hereditary cancer testing, the GALEAS Bladder clinical service, and a direct-to-consumer Hereditary Cancer Direct offering supported by the Gene Care genetic counselling partnership. Customers include NHS trusts (UCLH, Norfolk and Norwich, Dorset County Hospital, NHS Jewish BRCA Screening Programme), private hospitals (The London Clinic), academic institutions (University of Birmingham Bladder Cancer Research Centre), and population screening programmes (Protect-C, DETECT-2). The company is a subsidiary of Advanced Genomics Limited, holds ISO 13485:2016 and ISO 27001:2022 certifications, and announced a £5 million bladder cancer clinical trials investment with Cancer Research UK and the University of Birmingham in August 2025.

Name

Nonacus

Legal name

Nonacus Limited

Website

https://nonacus.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

51–100 employees

Short description

Nonacus is a Birmingham, UK-based medical products manufacturer founded in 2015 that develops non-invasive NGS-based liquid biopsy diagnostics for cancer, including UKCA-marked GALEAS Bladder and GALEAS Tumor tests, and delivers accredited clinical services to NHS trusts, private hospitals, academic researchers, and patients across 20+ countries.

Ownership category

akta.pro rank

Product category

Molecular Diagnostics / Genomic Testing

NAICS

Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Genomics & Next-Generation Sequencing (NGS) Services (HLAGANAA)

akta.pro secondary industries

Molecular Diagnostics & Genomics Laboratories (HLAFAMAE), Genetic, Cytogenetic & Prenatal Screening IVD (HLAHAAAI), Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Genetic & Prenatal Testing Laboratories (HLAFAMAH)

Keywords

• Next generation sequencing
• Liquid biopsy diagnostics
• Clinical genomic testing
• Target enrichment technology
• Hereditary cancer screening

Headquarters

HQ city

Birmingham

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. NGS Products (RUO): Sale of research use only (RUO) products including Cell3 Target library preparation kits, cfDNA extraction kits, targeted panels (GALEAS Bladder RUO, GALEAS Tumor RUO, GALEAS Hereditary RUO), Nexome whole exome kit, and custom panels. Products sold directly and through global distribution network. Revenue from one-time product purchases with recurring customer orders.
2. Clinical Testing Services: ISO 15189:2022 accredited clinical testing services delivered by Nonacus Clinical Services (formerly Informed Genomics). Services include GALEAS Bladder cancer testing, Hereditary Cancer panels (breast, ovarian, colorectal, prostate, melanoma, pancreatic), and Hereditary Cancer Direct direct-to-consumer offering. Revenue from service fees per test.
3. In Vitro Diagnostic Products (UKCA): UKCA marked diagnostic products including GALEAS Bladder (UKCA) and GALEAS Tumor (UKCA) for clinical use in UK. Regulatory-approved medical devices under UK Medical Devices Regulations 2002.
4. GALEAS Software Platform: Cloud-based bioinformatics platform for analysis and reporting of sequencing data. Software as a service model for clinical interpretation and reporting.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels7 records

Core offering

Nonacus designs, manufactures, and sells NGS-based genomic products and provides accredited clinical testing services for non-invasive cancer diagnostics. Its Cell3 Target enrichment chemistry and GALEAS bioinformatics platform power UKCA-marked IVD tests (GALEAS Bladder, GALEAS Tumor), research-use-only targeted and whole exome panels, pre-analytical cfDNA kits, custom NGS panels, and ISO 15189:2022-accredited clinical services delivered through Nonacus Clinical Services (formerly Informed Genomics).

Product overview

Nonacus offers a comprehensive portfolio of NGS-based genomic products and clinical services. The core technology is Cell3 Target, a target enrichment system for NGS library preparation compatible with all DNA types (gDNA, cfDNA, FFPE). The GALEAS platform provides an end-to-end solution combining Cell3 Target panels with cloud-based bioinformatics for cancer diagnostics. Product lines include: (1) In Vitro Diagnostic products UKCA-marked including GALEAS Bladder for bladder cancer detection and GALEAS Tumor for comprehensive genomic profiling (519 genes); (2) Clinical Research products (RUO) including GALEAS panels, Nexome whole exome kit, and Cell3 Target custom panels; (3) Pre-analytical products including cfDNA collection tubes and extraction kits; (4) Collaborative Design panels (PanHemeOnc, Actionable Mutation, Carrier Screening, Familial Hypercholesterolemia); (5) Clinical services including GALEAS Bladder service, Hereditary Cancer service, and Hereditary Cancer Direct with genetic counselling. The online Panel Design Tool enables custom NGS panel creation.

Differentiator

Problem solved

Functional benefit

Brands

• Cell3 Target: Target enrichment technology for generating next generation sequencing libraries from all DNA types (gDNA, FFPE and cfDNA)
• GALEAS
• Cell3 Preserver
• Bead Xtract
• Cell3 Xtract
• Nexome

Products and services

• GALEAS Bladder (UKCA) UKCA-marked in vitro diagnostic urine test for bladder cancer using a 23-gene targeted NGS panel; delivers >90% sensitivity equivalent to cystoscopy and detects 96% of bladder cancers across all stages and grades.
• GALEAS Tumor (UKCA) UKCA-marked comprehensive genomic profiling panel targeting 519 clinically relevant genes for solid tumors, detecting SNVs, indels, selected fusions, CNVs, TMB, MSI, and HRD in a single workflow.
• GALEAS Bladder (RUO) Research use only version of the GALEAS Bladder panel for bladder cancer biomarker detection in research settings.
• GALEAS Tumor (RUO) Research use only version of the comprehensive 519-gene genomic profiling panel for solid tumors.
• GALEAS Hereditary (RUO) NGS panel for hereditary cancer testing covering 38 genes (including BRCA1, BRCA2, MLH1, MSH2, MSH6, PMS2, PALB2, TP53) across breast, ovarian, colorectal, prostate, melanoma, and pancreatic cancer indications.
• Nexome Whole Exome Sequencing Kit Whole exome sequencing kit using Cell3 Target enrichment technology for comprehensive genomic analysis from gDNA, FFPE, and cfDNA samples.
• Cell3 Target Custom NGS Panels Custom targeted NGS panels designed using the Panel Design Tool, requiring as little as 10 ng DNA input and allowing detection of heterozygous mutations down to 0.1% VAF.
• Cell3 Target NGS Library Preparation Technology Target enrichment technology for generating next generation sequencing libraries from all DNA types (gDNA, FFPE, cfDNA); available in XS to XXL panel sizes with built-in dual indexes and UMIs for detection down to 0.1% VAF.
• Panel Design Tool Online software for creating custom NGS panel designs from BED files, gene lists, or genomic coordinates, with instant feedback on coverage, repetitive region masking, and exome gap-fill.
• cfDNA Collection Tubes (Cell3 Preserver) Cell-free DNA collection tubes (Cell3 Preserver) for stabilizing blood and urine samples prior to liquid biopsy processing.
• cfDNA Bead-Based Extraction Kit (Bead Xtract) Magnetic bead-based genomic DNA extraction kit for isolating tumor-derived cell-free DNA from liquid biopsy samples.
• cfDNA Spin Column Extraction Kit (Cell3 Xtract) Spin column-based cell-free DNA extraction kit for liquid biopsy sample processing.
• PanHemeOnc Panel Customer-designed collaborative NGS panel for lymphoid and myeloid cancer detection.
• Actionable Mutation Panel Customer-designed NGS panel targeting actionable mutations for clinical decision support.
• Carrier Screening Panel Customer-designed NGS panel for carrier screening of genetic disorders.
• Familial Hypercholesterolemia Panel Customer-designed NGS panel for detecting familial hypercholesterolemia genetic variants.
• GALEAS Bladder Clinical Service ISO 15189:2022 accredited end-to-end clinical testing service for bladder cancer risk assessment, from sample collection to clinical reporting, with results delivered within 10 working days.
• Hereditary Cancer Service ISO 15189:2022 accredited hereditary cancer testing service covering breast, ovarian, colorectal, prostate, melanoma, and pancreatic cancer indications, supporting NHS hereditary cancer programmes with results within 20 working days.
• Hereditary Cancer Direct Direct-to-consumer hereditary cancer testing service allowing patient self-referral or clinician referral via the genetictesting.nonacus.com portal, with genetic counsellor support delivered through Gene Care.
• GALEAS Cloud Bioinformatics Platform Cloud-based bioinformatics platform combining Cell3 Target panels with software for diagnostic reporting, supporting primary tumor analysis, longitudinal monitoring, MSI/HRD/TMB assessment, and MRD detection.

Quantifiable outcome

• GALEAS Bladder detects 96% of bladder cancers across all stages and grades
• +8 more outcomes

Named customers9 records

Segments6 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature5 records

Partnerships

Nine partnerships are on record, tiered flagship, core and minor.

• University of Birmingham (Clinical Trials Investment)flagshipStrategic or Co-development Partner · 15 August 2025University of Birmingham partners with Nonacus and Cancer Research UK on £5m bladder cancer clinical trials. Professor Richard Bryan continues academic collaboration on test development and validation.
• Gene CarecoreStrategic or Co-development Partner · 1 June 2025Nonacus Clinical Services partnered with Gene Care to deliver genetic counselling appointments for Hereditary Cancer Direct service. Gene Care's registered GCRB and AHCS genetic counsellors provide pre and post-test counselling support to patients.
• The London CliniccoreStrategic or Co-development Partner · 30 May 2025The London Clinic became the first independent hospital to offer GALEAS Bladder cancer tests in May 2025. Professor Prokar Dasgupta, Professor of Surgery and Urology, leading implementation.
• NHS Trusts (Dorset County Hospital Foundation Trust, University College London Hospitals NHS Foundation Trust, Norfolk and Norwich University Hospitals NHS Foundation Trust)coreStrategic or Co-development Partner · 8 January 2025Multiple NHS trusts are conducting service evaluations of GALEAS Bladder for bladder cancer diagnosis and haematuria triage. Dorset County Hospital leads the evaluation with 100% patient acceptance rate. University College London Hospitals and Norfolk and Norwich University Hospitals evaluating for clinical decision-making.
• NHS Jewish BRCA Screening ProgrammecoreStrategic or Co-development Partner · 1 January 2024Nonacus Clinical Services (Informed Genomics) is the laboratory partner for the NHS Jewish Community BRCA testing programme. Provides laboratory analysis, variant interpretation, and clinical reporting for hereditary breast and ovarian cancer screening in the Jewish community.
• Protect-C ProgrammeminorStrategic or Co-development Partner · 1 January 2024Population screening programme supported by Nonacus Clinical Services hereditary cancer testing capabilities.
• DETECT-2 ProgrammeminorStrategic or Co-development Partner · 1 January 2024Population screening initiative utilizing hereditary cancer testing services from Nonacus Clinical Services.
• University of Birmingham - Bladder Cancer Research CentrecoreStrategic or Co-development Partner · 1 January 2023GALEAS Bladder developed in partnership with researchers at University of Birmingham's Bladder Cancer Research Centre. Professor Richard Bryan leads academic collaboration. Test validated on UK clinical cohorts with 710+ samples.
• Advanced Genomics Limited (Parent Company)flagshipOthers · 1 January 2015Nonacus Limited and Informed Genomics Limited (trading as Nonacus Clinical Services) are subsidiaries of Advanced Genomics Limited. Group structure provides access to clinical services capabilities and regulatory infrastructure.

Scale indicators10 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Exact Sciences: Exact Sciences is a US diagnostics company focused on non-invasive cancer screening (Cologuard) and oncotype-style genomic testing. Its non-invasive screening and hereditary cancer product lines position it as a close strategic analogue to Nonacus's liquid biopsy and hereditary cancer franchises.
• Guardant Health: Guardant Health is a US-based leader in liquid biopsy and comprehensive genomic profiling for oncology. Both companies compete in NGS-based cfDNA tumour profiling and blood-based cancer detection, serving oncologists and biopharma with similar sample-to-report workflows.
• Personalis: Personalis is a US-based cancer genomics company offering NGS-based CGP and MRD testing for solid tumours. It competes with Nonacus in tumour profiling assays, pharma biopharma services, and ultra-sensitive ctDNA detection.
• NeoGenomics: NeoGenomics operates oncology-focused clinical laboratories offering CGP, liquid biopsy, and hereditary cancer testing. Following its acquisition of Inivata, it competes directly with Nonacus in NGS-based oncology diagnostics and clinical service delivery.
• Ambry Genetics: Ambry Genetics is a US-based clinical genetics laboratory offering hereditary cancer panels and exome-based testing. It is a direct peer to Nonacus's hereditary cancer testing services, including BRCA, Lynch syndrome, and multi-gene panels.
• Myriad Genetics: Myriad Genetics is a US-based hereditary cancer and oncology diagnostics company best known for BRCA testing and tumour profiling. Its hereditary cancer franchise directly overlaps with Nonacus's Hereditary Cancer panels and D2C service.
• Natera: Natera is a US-based cell-free DNA testing company with strengths in oncology MRD, hereditary cancer, and reproductive health. Nonacus's GALEAS Bladder, GALEAS Tumor, and Hereditary Cancer services target overlapping clinical use cases and customer segments.

Broad incumbents

• Illumina: Illumina is the dominant NGS platform and reagent provider globally. Nonacus's leadership team includes ex-Illumina commercial leaders, and Illumina's sequencing infrastructure underpins Nonacus's NGS workflows, making it both a supplier and a broad strategic incumbent in the same genomic medicine space.
• Foundation Medicine (Roche): Foundation Medicine, a Roche subsidiary, is a leading provider of comprehensive genomic profiling for solid tumours. It competes with Nonacus's GALEAS Tumor CGP service in oncology testing for clinicians and biopharma partners.

Regional players

• Nonacus Peer: Yourgene Health: Yourgene Health is a UK-based genomics company offering reproductive health, NIPT, and NGS-based clinical testing. As a regional UK peer, it competes with Nonacus in NHS genetic testing services and shares UK regulatory and reimbursement dynamics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/nonacusltd
• Facebookfacebook.com/nonacusltd
• LinkedInlinkedin.com/company/about
• Instagraminstagram.com/nonacus_

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nonacus